Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Gastroenterology

Staying Ahead: Cancer Risk and Surveillance Strategy

At a Glance

Juvenile Polyposis Syndrome (JPS) significantly increases the risk of gastrointestinal cancers, but routine, gene-specific screening for SMAD4 and BMPR1A mutations effectively prevents cancer by finding and removing polyps early. Regular surveillance is your best tool for long-term health.

Living with Juvenile Polyposis Syndrome (JPS) means adopting a new perspective on healthcare—one where prevention is the primary focus. Because JPS significantly increases the risk of developing gastrointestinal cancers over a lifetime, regular surveillance is not just a medical recommendation; it is your most powerful tool for staying healthy. By finding and removing polyps early, you and your medical team can stop cancer before it starts [1][2].

Understanding the Risks

Without regular screening, the lifetime risk of developing colorectal cancer is estimated to be between 39% and 68% [3]. The risk for gastric (stomach) cancer is also significant, ranging from 21% to 73% [4].

It is incredibly important to remember that these statistics often reflect historical outcomes without modern surveillance. With consistent monitoring and polyp removal (polypectomy), these risks can be managed and significantly lowered [5][1].

Tailoring Surveillance by Gene

Because different mutations carry different risks, your screening schedule should be “gene-specific” [6][7].

SMAD4 Carriers: A High-Alert Approach

If you have a SMAD4 mutation, your risk for stomach polyps and gastric cancer is much higher than in other forms of JPS [8][6].

  • Upper Endoscopy (EGD): Should often start early (around age 12–15, or even younger if symptoms appear) and be repeated every 1 to 2 years [4][9].
  • Colonoscopy: Typically performed every 1 to 3 years starting in the early teens [5].
  • HHT Screening: Because SMAD4 is linked to Hereditary Hemorrhagic Telangiectasia (HHT), you need additional check-ups for blood vessel malformations in the lungs (via a “bubble echo” ultrasound) and the brain (via MRI) [10][11]. You may also need your heart monitored for aortic dilation (widening of the main artery) [12].

BMPR1A Carriers: Focus on the Colon

For those with BMPR1A mutations, the risk is primarily centered in the large intestine [13].

  • Colonoscopy: Performed every 1 to 3 years, beginning in the early teens [5].
  • Upper Endoscopy (EGD): While still recommended, the risk of stomach cancer is notably lower for this group, and scans may be spaced differently than for SMAD4 carriers [13][6].

Managing “Scanxiety” and the Burden of Prep

It is completely normal to feel a surge of fear or stress before a medical scan—a feeling often called scanxiety [14][15]. The psychological toll of lifelong monitoring is a real, valid part of living with JPS.

  • The Waiting Game: Anxiety often peaks in the days between the scan and receiving the pathology results [14]. Ask your doctor for a clear timeline of when and how you will receive your results to help manage this window [16][17].
  • The Physical Toll: Preparing for colonoscopies (the “bowel prep”) is physically unpleasant and disruptive. Acknowledge this challenge, and speak with your doctor about modern prep options that might be easier to tolerate.
  • Finding Control: Many patients find that while scans are stressful, they also provide a sense of security and control over their health [15][18].
  • Support Systems: Utilizing peer-led online forums, social support, and patient advocacy networks can help mitigate the emotional burden [19][17].

Regular surveillance is a marathon, not a sprint. By staying committed to your schedule, you are actively protecting your future or the future of your child.

Common questions in this guide

How does Juvenile Polyposis Syndrome affect my cancer risk?
JPS significantly increases the lifetime risk of developing gastrointestinal cancers, particularly in the colon and stomach. However, consistent monitoring and polyp removal can effectively manage and significantly lower these risks.
What specific cancer screenings do SMAD4 mutation carriers need?
Individuals with a SMAD4 mutation face a higher risk for stomach polyps and require frequent upper endoscopies. Because SMAD4 is linked to Hereditary Hemorrhagic Telangiectasia, they also need regular screenings for blood vessel malformations in the lungs and brain, as well as heart monitoring.
How is surveillance different for BMPR1A mutation carriers?
For individuals with a BMPR1A mutation, the cancer risk is primarily focused in the large intestine. Surveillance heavily relies on regular colonoscopies every one to three years starting in the early teens, with a lower frequency of upper endoscopies compared to SMAD4 carriers.
How can I deal with the anxiety of regular cancer screenings?
It is completely normal to experience "scanxiety" before medical tests. You can manage this stress by asking your doctor for a clear timeline for results, exploring easier bowel prep options, and joining patient advocacy networks or support groups.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my genetic mutation (SMAD4 vs BMPR1A), what is my specific recommended interval for both colonoscopy and EGD?
  2. 2.For SMAD4 carriers, which HHT-specific screenings (like a brain MRI or bubble echocardiogram for the lungs) do we need to schedule, and at what age should these start?
  3. 3.Should we be monitoring for aortic dilation with regular echocardiograms or CT scans?
  4. 4.If we find polyps during a scan, how does that change the frequency of my next surveillance visit?
  5. 5.How can your office help reduce wait times for my scan results to help manage my anxiety?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Juvenile polyposis syndrome: An overview.

    Dal Buono A, Gaiani F, Poliani L, Laghi L

    Best practice & research. Clinical gastroenterology 2022; (58-59()):101799 doi:10.1016/j.bpg.2022.101799.

    PMID: 35988962
  2. 2

    Management of Juvenile Polyposis Syndrome in Children and Adolescents: A Position Paper From the ESPGHAN Polyposis Working Group.

    Cohen S, Hyer W, Mas E, et al.

    Journal of pediatric gastroenterology and nutrition 2019; (68(3)):453-462 doi:10.1097/MPG.0000000000002246.

    PMID: 30585890
  3. 3

    Juvenile polyposis syndrome: A case report.

    Pérez-Castilla A, Peñailillo P, Oksenberg D

    International journal of surgery case reports 2019; (59()):73-75 doi:10.1016/j.ijscr.2019.04.041.

    PMID: 31108454
  4. 4

    SMAD4 variants and its genotype-phenotype correlations to juvenile polyposis syndrome.

    Cao K, Plazzer JP, Macrae F

    Hereditary cancer in clinical practice 2023; (21(1)):27 doi:10.1186/s13053-023-00267-z.

    PMID: 38066625
  5. 5

    Malignant tumors associated with juvenile polyposis syndrome in Japan.

    Ishida H, Ishibashi K, Iwama T

    Surgery today 2018; (48(3)):253-263 doi:10.1007/s00595-017-1538-2.

    PMID: 28550623
  6. 6

    Occurrence of gastric cancer in patients with juvenile polyposis syndrome: a systematic review and meta-analysis.

    Singh AD, Gupta A, Mehta N, et al.

    Gastrointestinal endoscopy 2023; (97(3)):407-414.e1 doi:10.1016/j.gie.2022.10.026.

    PMID: 36265529
  7. 7

    Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers.

    Blatter R, Tschupp B, Aretz S, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2020; (22(9)):1524-1532 doi:10.1038/s41436-020-0826-1.

    PMID: 32398773
  8. 8

    Deciphering the clinical spectrum of gastric disease in patients with juvenile polyposis syndrome.

    Muller M, Baldysiak E, Benech N, et al.

    Gastrointestinal endoscopy 2024; (100(5)):867-877 doi:10.1016/j.gie.2024.05.015.

    PMID: 38777277
  9. 9

    Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer.

    Boland CR, Idos GE, Durno C, et al.

    Gastrointestinal endoscopy 2022; (95(6)):1025-1047 doi:10.1016/j.gie.2022.02.044.

    PMID: 35487765
  10. 10

    Case report of juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome: first report in Korea with a novel mutation in the SMAD4 gene.

    Kang B, Hwang SK, Choi S, et al.

    Translational pediatrics 2021; (10(5)):1369-1376 doi:10.21037/tp-21-12.

    PMID: 34189096
  11. 11

    Juvenile polyposis syndrome-hereditary hemorrhagic telangiectasia associated with a SMAD4 mutation in a girl.

    Hashimoto Y, Yokoyama K, Kumagai H, et al.

    Clinical journal of gastroenterology 2020; (13(6)):1096-1101 doi:10.1007/s12328-020-01238-w.

    PMID: 32944796
  12. 12

    SMAD4 gene mutation increases the risk of aortic dilation in patients with hereditary haemorrhagic telangiectasia.

    Vorselaars VMM, Diederik A, Prabhudesai V, et al.

    International journal of cardiology 2017; (245()):114-118 doi:10.1016/j.ijcard.2017.06.059.

    PMID: 28874282
  13. 13

    Genotype-phenotype correlation of BMPR1a disease causing variants in juvenile polyposis syndrome.

    Papadopulos ME, Plazzer JP, Macrae FA

    Hereditary cancer in clinical practice 2023; (21(1)):12 doi:10.1186/s13053-023-00255-3.

    PMID: 37400896
  14. 14

    Smartphone-based Ecological Momentary Assessment to study "scanxiety" among Adolescent and Young Adult survivors of childhood cancer: A feasibility study.

    Heathcote LC, Cunningham SJ, Webster SN, et al.

    Psycho-oncology 2022; (31(8)):1322-1330 doi:10.1002/pon.5935.

    PMID: 35411626
  15. 15

    Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

    Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

    Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

    PMID: 39343818
  16. 16

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  17. 17

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  18. 18

    Screening for Brain Metastases in Patients With NSCLC: A Qualitative Study on the Psychologic Impact of Being Diagnosed With Asymptomatic Brain Metastases.

    Schoenmaekers JJAO, Bruinsma J, Wolfs C, et al.

    JTO clinical and research reports 2022; (3(10)):100401 doi:10.1016/j.jtocrr.2022.100401.

    PMID: 36188631
  19. 19

    Experiences with scans and scanxiety in people with advanced cancer: a qualitative study.

    Bui KT, Blinman P, Kiely BE, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2021; (29(12)):7441-7449 doi:10.1007/s00520-021-06319-1.

    PMID: 34076779

This page provides educational information about Juvenile Polyposis Syndrome cancer risks and surveillance strategies. It does not replace professional medical advice. Always consult your gastroenterologist or genetic counselor regarding your personalized screening schedule.

Get notified when new evidence is published on Juvenile polyposis syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.